Merck (MSD) has entered a research collaboration with the Institute for Systems Biology (ISB) to study molecular mechanisms of SARS-CoV-2 and Covid-19 infection.
The partners aim to identify targets for drugs and vaccines against Covid-19. Findings from the research will be accessible to the scientific and biomedical community.
As part of the project, ISB, the Swedish Medical Center, and a consortium of research organisations and biomedical companies will test blood samples and nasal swabs.
The samples and swabs will be obtained at different time points from Covid-19 patients at the Swedish Medical Center. Proteomic, metabolomics, transcriptomic and genetic approaches will be used to analyse blood samples for Covid-19’s effect on